{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-037559","form_type":"8-K","ticker":"MD","cik":"0000893949","company_name":"Pediatrix Medical Group, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.912877+00:00","generated_at":"2026-06-12T10:36:35.863316+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pediatrix Q2 net revenue $500.6M (+3% YoY); GAAP EPS $0.34, adjusted $0.39; EBITDA $59M","bullets":["GAAP EPS from continuing ops $0.34 vs $0.36; adjusted EPS $0.39 vs $0.47 in prior year.","Adjusted EBITDA $59.1M vs $65.6M YoY; 2023 EBITDA guidance reaffirmed at $235-245M.","Same-unit revenue up 3.2% (reimbursement +2.6%, volume +0.6%); no CARES Act funds in Q2.","Cash from ops $92.6M (+$11M YoY); capex $8.1M; total debt $675M.","Weighted average shares fell to 82.7M from 85.6M due to share repurchases."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-037559","json":"https://secwatch.observer/filing/0000950170-23-037559.json","markdown":"https://secwatch.observer/filing/0000950170-23-037559.md","text":"https://secwatch.observer/filing/0000950170-23-037559.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/893949/000095017023037559/0000950170-23-037559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/893949/000095017023037559/md-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T10:36:35.863316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03a906457b6a5c1b70dbfefd0d83dcd467aa3b96","claim":"Pediatrix Medical Group, Inc. reported six months ended June 30, 2023 results: revenue $991.6 million, net income $42.5 million, EPS $0.52 per share.","evidence_excerpt":"Operating Results from Continuing Operations – Six Months Ended June 30, 2023 For the six months ended June 30, 2023, Pediatrix generated revenue from continuing operations of $991.6 million, compared to $968.3 million for the prior-year period. Adjusted EBITDA from continuing operations for the six months ended June 30, 2023 was $99.2 million, compared to $116.2","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/893949/000095017023037559/0000950170-23-037559-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"six months ended June 30, 2023"},{"label":"Revenue","value":"$991.6 million"},{"label":"Net income","value":"$42.5 million"},{"label":"EPS","value":"$0.52 per share"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"977e6a7e183e37dbb868e6cb7c409d121b87a042","claim":"Pediatrix Medical Group, Inc. reported three months ended June 30, 2023 results: revenue $500.6 million, net income $28.3 million, EPS $0.34 per diluted share.","evidence_excerpt":"reported Adjusted EPS from continuing operations of $0.39. For the 2023 second quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $501 million; • Income from continuing operations of $28 million; and • Adjusted EBITDA of $59 million. “Our second quarter operating results were in line with our expectations and reflect","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/893949/000095017023037559/0000950170-23-037559-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended June 30, 2023"},{"label":"Revenue","value":"$500.6 million"},{"label":"Net income","value":"$28.3 million"},{"label":"EPS","value":"$0.34 per diluted share"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}